Form 8-K - Current report:
SEC Accession No. 0001437749-25-010187
Filing Date
2025-03-31
Accepted
2025-03-31 16:10:11
Documents
16
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K allr20250331_8k.htm   iXBRL 8-K 30008
2 EXHIBIT 99.1 ex_796943.htm EX-99.1 104602
7 atlogosmall.jpg GRAPHIC 5907
  Complete submission text file 0001437749-25-010187.txt   302837

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA allr-20250331.xsd EX-101.SCH 3579
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE allr-20250331_def.xml EX-101.DEF 12187
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE allr-20250331_lab.xml EX-101.LAB 16396
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allr-20250331_pre.xml EX-101.PRE 12457
18 EXTRACTED XBRL INSTANCE DOCUMENT allr20250331_8k_htm.xml XML 3037
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 25793276
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)